These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37505272)

  • 1. An IQ consortium analysis of starting dose selection for oncology small molecule first-in-patient trials suggests an alternative NOAEL-based method can be safe while reducing time to the recommended phase 2 dose.
    Jessen BA; Cornwell P; Redmond S; Visalli T; Lemper M; Bunch T; Hart T
    Cancer Chemother Pharmacol; 2023 Dec; 92(6):455-464. PubMed ID: 37505272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs.
    Mittapalli RK; Yin D; Beaupre D; Palaparthy R
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):23-30. PubMed ID: 33237334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An FDA oncology analysis of antibody-drug conjugates.
    Saber H; Leighton JK
    Regul Toxicol Pharmacol; 2015 Apr; 71(3):444-52. PubMed ID: 25661711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013.
    Nikanjam M; Liu S; Kurzrock R
    Int J Cancer; 2016 Nov; 139(9):2135-41. PubMed ID: 27389805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials.
    Hazim A; Mills G; Prasad V; Haslam A; Chen EY
    J Natl Compr Canc Netw; 2020 Apr; 18(4):428-433. PubMed ID: 32259790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials.
    Hansen AR; Cook N; Ricci MS; Razak A; Le Tourneau C; McKeever K; Roskos L; Dixit R; Siu LL; Hinrichs MJ
    Oncologist; 2015 Jun; 20(6):653-9. PubMed ID: 25964306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicologic Pathology Forum: Opinion on Approaches for Reporting Toxic and Adverse Dose Levels in Nonclinical Toxicology Studies Supporting the Development of Anticancer Pharmaceuticals.
    Hukkanen RR; Moriyama T; Patrick DJ; Werner J
    Toxicol Pathol; 2023 Jan; 51(1-2):81-86. PubMed ID: 36695335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing benefit/risk in oncology: Review of post-marketing dose optimization and reflections on the road ahead.
    Soltantabar P; Lon HK; Parivar K; Wang DD; Elmeliegy M
    Crit Rev Oncol Hematol; 2023 Feb; 182():103913. PubMed ID: 36681205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the starting dose for entry into humans: principles and practice.
    Reigner BG; Blesch KS
    Eur J Clin Pharmacol; 2002 Feb; 57(12):835-45. PubMed ID: 11936701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncology dose optimization paradigms: knowledge gained and extrapolated from approved oncology therapeutics.
    Mittapalli RK; Guo C; Drescher SK; Yin D
    Cancer Chemother Pharmacol; 2022 Sep; 90(3):207-216. PubMed ID: 35965268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials.
    Penel N; Duhamel A; Adenis A; Devos P; Isambert N; Clisant S; Bonneterre J
    Invest New Drugs; 2012 Apr; 30(2):653-61. PubMed ID: 21049280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons Learned: Dose Selection of Small Molecule-Targeted Oncology Drugs.
    Bullock JM; Rahman A; Liu Q
    Clin Cancer Res; 2016 Jun; 22(11):2630-8. PubMed ID: 27250934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials.
    Le Tourneau C; Stathis A; Vidal L; Moore MJ; Siu LL
    J Clin Oncol; 2010 Mar; 28(8):1401-7. PubMed ID: 20124167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extrapolation of Oligonucleotide Dose Levels Used in Nonclinical Toxicity Studies to Selection of Safe Starting Dose Levels in Human Clinical Trials.
    Kornbrust D
    Nucleic Acid Ther; 2019 Jun; 29(3):123-125. PubMed ID: 30817231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.
    Colin P; Micallef S; Delattre M; Mancini P; Parent E
    Stat Med; 2015 Sep; 34(22):2999-3016. PubMed ID: 26059319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
    Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
    Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
    Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
    J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.
    Venkatakrishnan K; Pickard MD; von Moltke LL
    Clin Pharmacokinet; 2010 Nov; 49(11):703-27. PubMed ID: 20923246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection.
    Saber H; Del Valle P; Ricks TK; Leighton JK
    Regul Toxicol Pharmacol; 2017 Nov; 90():144-152. PubMed ID: 28887049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.